Stefanie Aeppli
Papers
1
Total Citations
32
H-Index
1
About
Stefanie Aeppli is a leading clinical investigator in genitourinary oncology, with a primary focus on improving outcomes for patients with muscle-invasive urothelial carcinoma (MIUC). Her work centers on the development of novel perioperative treatment strategies, particularly the integration of immunotherapy with standard chemotherapy. Her most cited work, a preplanned interim analysis of the single-arm phase II trial SAKK 06/17, investigates the combination of the PD-L1 inhibitor durvalumab with cisplatin/gemcitabine in the neoadjuvant setting. This study, which has garnered 32 citations, addresses the critical need to reduce high relapse rates following standard cisplatin-based chemotherapy and surgery. By pioneering chemoimmunotherapy regimens for operable MIUC, Aeppli is at the forefront of translating the success of immune checkpoint inhibitors from advanced disease into earlier, potentially curative stages. Her research directly impacts clinical practice, offering new hope for patients with this aggressive cancer.
Research Focus
Key Achievements
Top Papers
- 1